NCT07258745招募中1 期
A Randomized, Double-Blind, Single-Dose, Parallel-Group, Three-Arm Trial to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity Profiles of CKD-704 (Risankizumab Biosimilar), EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 213
- 试验地点
- 1
- 主要终点
- Maximum Observed Serum Concentration (Cmax)
研究概览
简要总结
This is a Phase 1, first-in-human (FIH), randomized, double-blind, single-dose, parallel-group, 3-arm study to compare PK, safety, tolerability, and immunogenicity profiles of CKD-704, EU-approved Skyrizi, and US-licensed Skyrizi in healthy adult participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Capability of giving signed informed consent and complying with the requirements and restrictions listed in the ICF and Protocol
- •Healthy male or female, 18 to 55 years (inclusive) at the time of signing the ICF
- •smokes ≤ 10 cigarettes per week within 3 months of screening
- •abstain from alcohol from 48 hours prior to study intervention administration and keeping alcohol consumption within WHO limits (more than 14 units per week spread over 3 or more days, equivalent to 6 pints of average strength beer or 6 medium glasses [175 mL] of wine)
- •have acceptable venous access for blood collection
- •Female participants are eligible to participate if they are not pregnant, not breastfeeding
- •Male participants must refrain from donating sperm from screening (signing the ICF) until at least 30 days after EOS visit
- •All participants must be willing to use effective/highly effective methods of contraception during the study period
- •Participants are willing and able to be confined to the clinical unit prior to and during the study intervention administration and required follow-up periods.
排除标准
- •History of previous exposure to any anti-IL-12/23 or anti-IL-23 treatment
- •History of relevant drug and/or food allergies
- •History of hypersensitivity to Skyrizi or their constituents
- •Presence of psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary procedures
- •Medical history, findings of physical examination/laboratory tests indicate a clinically significant disorder, condition, or disease that, in the opinion of the Investigator would pose a risk to participant safety
- •Major surgery within 12 weeks prior to the randomization into the study
- •Documented active or suspected malignancy or history of malignancy within 5 years prior to screening
- •Positive tests for hepatitis B surface antigen, Hepatitis B core antibody, hepatitis C virus antibody, or human immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening
- •Positive test for severe acute respiratory syndrome coronavirus 2 on admission (optional)
- •Any current active infections or any recent history (within 1 week prior to study intervention administration) of active infections
- •Participant has a history of tuberculosis (TB) diagnosis or evidence of active or latent infection with Mycobacterium tuberculosis
- •Abnormal hepatic, renal, or hematological laboratory tests. In such cases, the assessment may be repeated once at screening and admission. The Investigator will check reassessment results to decide if the value is clinically significant and if participant is eligible to receive the treatment
- •Any other laboratory value outside the reference range that the Investigator considers to be of clinical significance
- •Abnormal vital signs(Systolic blood pressure < 90 mmHg or > 140 mmHg, Diastolic blood pressure < 50 mmHg or > 90 mmHg, Heart rate < 45 or > 100 beats per minute)
- •Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG and any clinically important abnormalities in the 12-lead ECG
- •Any past or concurrent medical conditions, or clinically important active infection that could potentially increase the participant's risks or that would interfere with the study evaluation, procedures, or study completion
- •Have used any prescription or non-prescription medicines or vitamins within 7 days or 5 half-lives (whichever is longer) of admission, unless in the Investigator's opinion will not affect determination of safety or other study assessments
- •Male or females participating in any other clinical trial at the time of consenting
- •Have received any investigational drug within 30 days prior to screening, with minimal washout of at least 5-half-lives of any previous investigational drug, whichever is longer
- •Have received live vaccines during the past 4 weeks before screening or have the intention to receive vaccination during the 21-week treatment and assessment period
- •Participant has donated blood (> 500 mL) or blood products within 2 months (56 days) prior to screening
- •History of drug abuse or alcohol abuse as judged by the Investigator or designee
- •Participant is affiliated with the site or Sponsor and/or may be considered to be consenting under duress
- •Participant is unlikely to co-operate with the requirements of the study
研究组 & 干预措施
CKD-704
Experimental
Singe dose pre-filled syringe, 150mg/ml
干预措施: CKD-704 (Biological)
EU-Skyrizi
Active Comparator
Singe dose pre-filled syringe, 150mg/ml
干预措施: SKYRIZI (Biological)
US-Skyrizi
Active Comparator
Singe dose pre-filled syringe, 150mg/ml
干预措施: SKYRIZI (Biological)
结局指标
主要结局
Maximum Observed Serum Concentration (Cmax)
时间窗: up to approximately 146 days
Maximum observed serum concentration (Cmax) of risankizumab.
AUC From Time 0 to Infinity (AUCinf)
时间窗: Up to approximately 146 days
AUCinf of risankizumab
次要结局
- Area Under Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt)(Up to approximately 146 days)
- Terminal Phase Elimination Hhalf-life (t1/2)(Up to approximately 146 days)
- Time to Cmax (Tmax)(Up to approximately 146 days)
- Safety and tolerability(Up to approximately 146 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)PsoriasisNCT04744363Alvotech Swiss AG294
已完成
1 期
A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®Psoriatic ArthritisNCT05332730Bio-Thera Solutions375
已完成
1 期
A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy SubjectsInflammatory DiseaseNCT05857215Galmed Pharmaceuticals Ltd55
已完成
1 期
To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed AvastinHealthyNCT03247673Celltrion141
已完成
1 期
The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.InfluenzaNCT03679143Guangdong Zhongsheng Pharmaceutical Co., Ltd.103